In Reply
- PMID: 32969114
- PMCID: PMC7648355
- DOI: 10.1002/onco.13538
In Reply
Abstract
This letter to the editor responds to remarks on the authors' recently published article on the role of HER2 as a negative prognostic factor in completely resected biliary tract cancer.
Comment on
-
HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer.Oncologist. 2020 Oct;25(10):886-893. doi: 10.1634/theoncologist.2019-0922. Epub 2020 May 11. Oncologist. 2020. PMID: 32353192 Free PMC article.
-
Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer".Oncologist. 2020 Nov;25(11):e1818. doi: 10.1634/theoncologist.2020-0385. Epub 2020 Aug 13. Oncologist. 2020. PMID: 32715579 Free PMC article. No abstract available.
References
-
- NCCN guidelines version 2. 2020 Hepatobiliary Cancers. Available at https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed May 21, 2020.
-
- Primrose JN, Fox RP, Palmer DH et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20:663–673. - PubMed
-
- Morgan AM, Amir E, Walter T et al. Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta‐analysis. J Clin Oncol 2012;30:1934–1940. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous